May 2022 Newsletter

Publications

>> Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases

Researchers develop a multisystem platform based on induced pluripotent stem cells derived from a Leigh-like syndrome patient with variants in the ECHS1 gene to assess therapeutic compounds and guide clinical trial selection.

Sequiera GL, Srivastava A, et al. (2022). Science Advances.

Read now

>> Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells

The authors establish a method to generate induced pluripotent stem cell-derived motor neurons from people with ALS for the purpose of high-throughput drug screening and investigation of the FDA-approved medication edaravone.

Li Q, Feng Y, et al. (2022). Molecular Neurodegeneration.

Read now

>> Transcription factor 4 loss-of-function is associated with deficits in progenitor proliferation and cortical neuron content

Scientists investigate the pathological mechanisms of transcription factor 4 and explore therapeutic targets for the rare autism spectrum disorder Pitt-Hopkins syndrome using neural progenitor cells, neurons, and brain cortical organoids.

Papes F, Camargo AP, et al. (2022). Nature Communications.

Read now

>> Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons

Discover how scientists established a population-based human induced pluripotent stem cell (hiPSC) drug screening platform to assess cardiotoxicity and neurotoxicity in 1,000 healthy volunteers—findings that may advance precision medicine.

Huang CY, Nicholson MW, et al. (2022). Cell Reports.

Read now

News

>> Neurons: In the Know

Axion’s Chief Technology Officer Jim Ross discusses how researchers are using 3D cerebral organoids to explore the development of neural networks over time and accelerate the discovery of novel therapeutics.

Read now

Upcoming Events

>> Discovery Europe
Berlin, Germany / June 9-10

Stop by our booth to learn how Axion's advanced Maestro platforms are accelerating drug discovery and enabling innovative in vitro research with 3D organoids.

>> XVIII International Parvovirus Workshop
Rimini, Italy / June 14-17

Visit our booth to discover how Axion's noninvasive Maestro platforms continuously monitor in vitro viral infections in real time to capture the full range of cytopathic effects.

>> International Society for Stem Cell Research (ISSCR) San Francisco, CA / June 15-18

Join us to learn how Axion's next-generation Maestro platforms are influencing stem cell research and discovery around the world.

>> Onco Cell Therapy Summit (OCTS)
Boston, MA / June 29-30

Visit our booth to discover how Axion's label-free cell growth and killing assays on the Maestro platforms are transforming immunotherapy discovery.

Travel Awards

Axion BioSystems is proud to support researchers as they share their scientific discoveries and Maestro data at conferences around the world. Apply for your travel award today.

>> Pascal Röderer, University Hospital Bonn

Apply now

axionbio.com